ERS

September 20, 2017September 20, 2017

FibroGen’s Pamrevlumab Slows Lung Function Decline in IPF Patients, Trial Results Show

Lung function decline in patients with idiopathic pulmonary fibrosis (IPF) was slowed by the investigational drug pamrevlumab, according to the results from a Phase 2b clinical trial. The results were presented ... Read more

September 8, 2017September 8, 2017

miRagen Therapeutics to Present New Promising Data on MRG-201 at ERS 2017

Idiopathic Pulmonary Fibrosis, News

miRagen Therapeutics, a biopharmaceutical company involved in the discovery of RNA-based therapies, will present new preclinical safety and feasibility data for the therapy MRG-201 in the treatment of pulmonary fibrosis at the ... Read more

April 3, 2017April 3, 2017

Stem Cells Reduce Lung Inflammation and Damage in Mouse Model of COPD and Cystic Fibrosis

COPD, Cystic Fibrosis, News

A ground-breaking experiment using mesenchymal stem cells (MSCs) injected into mice models of chronic obstructive pulmonary disease (COPD) and cystic fibrosis showed that MSC therapy might be a promising approach to ... Read more

October 2, 2015November 9, 2015

COPD Foundation and ViiMed Launch COPD360coach Virtual Interactive Program Offering Better Care Solutions for COPD Patients

COPD, News

The COPD Foundation and medical software developer ViiMed this week announced the launch of COPD360coach at the European Respiratory Society International Congress in Amsterdam. Development of COPD360coach stems from a ... Read more